Lumiera Health Inc. (TSXV: NHP) (the 'Company' or 'Lumiera '), a company specializing in the development and commercialization of natural health products, is announcing that it intends to sell, on a private placement basis, in one or more tranches, up to 52,000,000 units (the 'Units') at a price of $0.025 per Unit, for gross proceeds to the Company of up to $1.3 million.
The issue price of the Units is equal to the closing price of the Lumiera shares on the TSX Venture Exchange on June 17, 2021.
Each Unit will consist of one common share in the capital of the Company (each, a 'Common Share') and one common share purchase warrant (each, a 'Warrant'), with each Warrant entitling the holder to acquire one additional Common Share, at an exercise price of $0.06 per share, for a period of four years from the date of issuance. The Company intends to include an acceleration clause in the certificates representing the Warrants whereby the Company may accelerate the expiry of these Warrants at any time prior to the expiry date in the event the daily volume weighted average trading price of the Common Shares of the Company on the TSX Venture Exchange exceeds $0.12 for at least 10 consecutive trading days by providing written notice to the warrant holders (the 'Acceleration Notice'). The Warrants will, unless exercised, expire on the 30th day after the Company provides the Acceleration Notice. The Company may pay registered dealers a cash commission equal to up to 7.5% of the aggregate proceeds raised in the private placement and issue broker warrants entitling such dealers to purchase such number of Units equal to up to 7.5% of the aggregate of number of Units issued in the private placement, at the same issue price as the Units. The final terms of the broker warrants will be confirmed prior to closing. The offering is expected to close on or before July 9, 2021. The net proceeds from the private placement are intended to be used for working capital to support revenue growth and for general corporate purposes. ' We have made great progress in the past couple of months and the added capital will enable us to accelerate our growth as we continue on our expected path toward profitability', said Carlos Ponce, CEO of Lumiera.
The closing of the private placement is subject to certain standard conditions including, but not limited to, the receipt of all necessary approvals including the acceptance of the TSX Venture Exchange.
About Lumiera Health Lumiera specializes in the development and commercialization of evidence-based botanical products for the healthcare industry. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Lumiera is also developing and commercializing a unique portfolio of products acting on the endocannabinoid system and providing innovative solutions for chronic pain and inflammation. The Company is a pioneer in the health and pain management innovation space and the Lumiera brand is rooted in the core brand values of science, nature and compassion. Passionate about making people feel better, we deliver trustworthy and scientifically proven solutions that work with the body's own system.
Forward-looking information
Certain statements contained in this press release constitute 'forward-looking information' as such term is defined in applicable Canadian securities legislation. The words 'may', 'would', 'could', 'should', 'potential', 'will', 'seek', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'expect' and similar expressions indicate such 'forward-looking information' as they relate to Lumiera. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Lumiera' current views and intentions with respect to future events, and current information available to Lumiera, and are subject to certain risks, uncertainties and assumptions. Such risks and uncertainties include, among others, the risk factors included in Lumiera' annual management's discussion and analysis for the year ended November 30, 2020, which is available under the issuer's SEDAR profile at www.sedar.com. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Lumiera in an unexpected manner, or should assumptions underlying the forwardlooking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Lumiera does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Lumiera undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Contact:
Tel: 514-880-7772
Email: scastonguay@lumiera.ca
LUMIERA HEALTH INC. 